CompletedPHASE1, PHASE2NCT05211830
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
Studying Netherton syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sixera Pharma
- Principal Investigator
- Maarten de Chateau, MD PhDSixera Pharma
- Intervention
- SXR1096 cream(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2025
Study locations (5)
- Medical University Innsbruck, Tirol Kliniken, Innsbruck, Austria
- Saint Louis Hospital, Paris, France
- Necker Hospital, Paris, France
- University of Freiburg, Freiburg im Breisgau, Germany
- Karolinska Hospital, Huddinge, Stockholm, Sweden
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05211830 on ClinicalTrials.govOther trials for Netherton syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals
- RECRUITINGPHASE1NCT06539507A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725BioCryst Pharmaceuticals
- RECRUITINGPHASE1NCT06137157Evaluation of Topical ATR12-351 in Adults With Netherton SyndromeAzitra Inc.
- RECRUITINGPHASE2, PHASE3NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05521438Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals